Top Page
Extrawell Pharmaceutical Holdings Limited
(0858)
Extrawell Pharmaceutical Holdings Limited (0858) vs. iShares MSCI Hong Kong ETF (EWH)
Extrawell Pharmaceutical Holdings Limited Business Overview & Revenue Model
Extrawell Pharmaceutical Holdings Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 55.43M | 55.43M | 59.10M | 72.58M | 73.92M | 78.80M |
| Gross Profit | 21.87M | 21.87M | 28.78M | 31.14M | 37.56M | 42.57M |
| EBITDA | 257.29M | 255.11M | -129.52M | 155.20M | 157.84M | -97.48M |
| Net Income | 222.64M | 222.64M | -162.95M | 129.26M | 130.59M | -121.10M |
Balance Sheet | ||||||
| Total Assets | 1.53B | 1.53B | 1.29B | 1.44B | 1.32B | 1.16B |
| Cash, Cash Equivalents and Short-Term Investments | 994.86M | 994.86M | 95.01M | 123.96M | 135.52M | 150.18M |
| Total Debt | 140.94M | 140.94M | 120.41M | 615.58M | 597.67M | 586.23M |
| Total Liabilities | 191.55M | 191.55M | 174.58M | 671.28M | 659.53M | 642.36M |
| Stockholders Equity | 1.33B | 1.33B | 1.11B | 769.36M | 653.29M | 518.15M |
Cash Flow | ||||||
| Free Cash Flow | 119.00K | -7.44M | -4.89M | -3.40M | -11.23M | -953.00K |
| Operating Cash Flow | 119.00K | -4.37M | -3.69M | 3.21M | -1.60M | -232.00K |
| Investing Cash Flow | 602.00K | -9.38M | 2.04M | -12.50M | -9.63M | -681.00K |
| Financing Cash Flow | -855.00K | -1.58M | -6.50M | -2.29M | -1.80M | -1.69M |
Extrawell Pharmaceutical Holdings Limited Technical Analysis
Extrawell Pharmaceutical Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$226.95M | -0.64 | -32.04% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$595.53M | -3.16 | -40.38% | ― | -43.46% | -96.48% | |
48 Neutral | HK$211.34M | -40.20 | -8.71% | ― | 2.54% | 33.33% | |
47 Neutral | HK$46.60M | -4.92 | -2.40% | ― | -40.37% | -112.64% | |
46 Neutral | HK$172.94M | -0.48 | -41.48% | ― | 6.55% | -475.22% | |
41 Neutral | HK$187.23M | -3.59 | -33.22% | ― | -17.32% | 55.74% |
Extrawell Pharmaceutical Holdings Limited Corporate Events
Extrawell Pharmaceutical Holdings Limited has announced that, effective 1 January 2026, the building name of its Hong Kong head office and principal place of business will change from Devon House to FWD Tower, with the full updated address now stated as Suites 2206–08, 22/F., FWD Tower, Taikoo Place, 979 King’s Road, Quarry Bay, Hong Kong. The change is purely nominal and does not involve any relocation, meaning the physical location and operational footprint of the company in Hong Kong remain unchanged, signalling no direct impact on ongoing business activities or stakeholder arrangements beyond administrative address updates.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical’s indirect subsidiary Changchun Extrawell has agreed to buy back a 10.06% equity stake from an existing substantial shareholder for RMB4.4 million, with the repurchased shares to be cancelled, raising the group’s interest in Changchun Extrawell from 80.46% to 89.46%. The transaction, classified as a discloseable and connected transaction at the subsidiary level under Hong Kong Listing Rules, has been approved by the board and endorsed as fair and reasonable by independent non-executive directors, is exempt from circular and independent shareholders’ approval requirements, and follows an earlier 2023 buy-back that previously lifted the group’s stake, underscoring Extrawell’s ongoing strategy to consolidate control of this key subsidiary while cautioning investors that completion remains subject to conditions precedent.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings has announced a leadership reshuffle effective 1 January 2026, separating the roles of chairman and chief executive officer as part of a broader push to enhance corporate governance and meet its evolving development needs. Long-serving chairman and CEO Dr. Xie Yi will step down from the chief executive role to concentrate on the company’s strategic direction while remaining as chairman and an executive director, with the board noting there is no disagreement behind his change in role. Executive director and genetics specialist Dr. Guo Yi, who has a background in biomedicine, healthcare and investment management and currently serves as a director of certain group subsidiaries, will take over as CEO without additional remuneration beyond his existing executive package and share options. The board underscored that the changes aim to improve segregation of duties and governance standards, signaling a more institutionalised management structure that may strengthen oversight and strategic execution for shareholders as the group pursues further growth in biomedicine and related fields.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings Limited, a Hong Kong-listed pharmaceutical company focused on the development, manufacture and sale of healthcare and drug products in Greater China, has announced the composition of its board and key governance committees effective 1 January 2026. The company confirmed a board led by Chairman Dr. Xie Yi and CEO Dr. Guo Yi, supported by executive and independent non-executive directors, and detailed the structure of its Audit, Remuneration and Nomination Committees, with independent non-executive director Mr. Fang Lin Hu chairing both the Audit and Remuneration Committees and Dr. Xie Yi chairing the Nomination Committee, underscoring the firm’s emphasis on corporate governance and oversight as it heads into the new year.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings Limited has granted a total of 76.5 million share options, representing about 3% of its issued share capital, to three executive directors under its 2022 share option scheme. The options, granted on 19 December 2025 at an exercise price of HK$0.0936 per share, will vest 12 months after the grant date and can be exercised for up to 10 years thereafter, with a nominal acceptance consideration and no performance targets attached, but subject to a clawback mechanism tied to misconduct and employment termination. The move underscores the company’s use of equity-based incentives to align management interests with shareholders, while limiting dilution through a relatively small percentage of new shares and confirming no financial assistance was provided to grantees for exercising the options.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings Limited has announced a major transaction involving the Fourth Amendment Deed with Starcoin, which proposes changes to the terms and conditions of existing bonds. These amendments include adjustments to the principal amount, conversion price, interest rate, and maturity date of the bonds. The transaction is significant, as it constitutes a major transaction under the Listing Rules, requiring shareholder approval. The announcement highlights the company’s ongoing efforts to manage its financial instruments and obligations, reflecting its strategic focus on optimizing financial terms and conditions to align with its business goals.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings Limited announced its unaudited consolidated results for the six months ending September 30, 2025, revealing a decrease in total assets from HK$1,526,352,000 to HK$1,098,039,000. The company also reported a decline in equity attributable to owners from HK$1,334,542,000 to HK$892,643,000, indicating financial challenges that may impact its operations and market positioning.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
Extrawell Pharmaceutical Holdings Limited has issued a profit warning, indicating an expected loss between HK$450 million and HK$480 million for the six months ending September 30, 2025, compared to a profit in the same period in 2024. This anticipated loss is primarily due to an unrealized loss on the fair value of investments in convertible bonds, despite steady performance in its operating segments. The interim results are yet to be confirmed and will be published by the end of November 2025.
Extrawell Pharmaceutical Holdings Limited has announced a board meeting scheduled for November 28, 2025, to approve the interim results for the six months ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders and the company’s market positioning.